Hint | Answer | % Correct |
---|---|---|
dopamine | 81%
| |
serotonin | 75%
| |
serotonin | 75%
| |
what are the drug types used to treat depression? | SSRIs (selective serotonin reuptake inhibitors) | 75%
|
what is an example of each of these drug types? | escitalopram, sertraline, etc | 69%
|
control of appetite, sleep, mood, hallucinations, pain perception and vomiting | 63%
| |
what is an example of each of these drug types? | diazepam, lorazepam, etc | 63%
|
noradrenaline | 63%
| |
noradrenaline | 63%
| |
SNRIs (serotonin-noradrenaline reuptake inhibitors) | 56%
| |
what neurotransmitters are anxiety symptoms mediated by? | GABA | 50%
|
what are the main neurotransmitters of the CNS? | GABA | 50%
|
what are the two main drug types that are used to treat anxiety? | benzodiazepines | 44%
|
what is depression characterised by? | low mood, lack of motivation and interest, and aversion to activity | 44%
|
MAOIs (monoamine oxidase inhibitors) | 44%
| |
TCAs (tricyclic antidepressants) | 44%
| |
venlafaxine, desvenlafaxine, etc | 38%
| |
inhibits serotonin, sigma, muscarinic, NMDA and histamine receptors | 31%
| |
what is anxiety characterised by? | a feeling of dread, apprehension or uneasiness that often arises from an unknown source | 25%
|
amitriptyline, amoxapine, etc | 25%
| |
barbiturates | 25%
| |
what is their mechanism of action? | binding to allosteric site of GABA-A receptors to enhance GABA binding | 25%
|
blocks the reuptake of serotonin and noradrenaline back into the pre-synaptic cell | 25%
| |
blocks the reuptake of serotonin and noradrenaline back into the pre-synaptic cell, meaning that both neurotransmitters stay in the synaptic gap longer and may bind again to their receptors | 25%
| |
phenobarbitone, amobarbitone, etc | 25%
| |
pirlindole, selegiline, etc | 25%
| |
what is their mechanism of action? | selectively blocks the reuptake of serotonin back into the pre-synaptic cell, meaning that free serotonin stays in the synaptic gap longer and may bind again to serotonin receptors | 25%
|
increases arousal and alertness | 19%
| |
what is thought to be the pathophysiology of depression? | insufficient monoamine neurotransmitter activity | 19%
|
what is thought to be the pathophysiology of anxiety? | involves neurochemical dysfunction (e.g. decreased GABA-ergic tone, increased cortisol expression) and/or dysfunction of the amygdala in the brain | 13%
|
what is the function of each in the CNS? | mediates majority of inhibitory post-synaptic potentials | 13%
|
what is the aims of pharmacological treatment of depression? | restore monoamine neurotransmitter activity | 13%
|
inhibits the activity of monoamine oxidase A and/or B, preventing the enzymes from breaking down monoamine neurotransmitters, increasing their availability | 6%
|
Copyright H Brothers Inc, 2008–2024
Contact Us | Go To Top | View Mobile Site